Amyloid-beta42/Neurogranin Ratio as a Potential Index for Cognitive Impairment in Parkinson's Disease
Authors/Creators
- 1. IRCCS Fondazione Santa Lucia, and Department of Experimental Medicine and Surgery, University of Roma Tor Vergata, Rome, Italy
- 2. Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy
- 3. Department of Experimental Medicine and Surgery, University of Roma Tor Vergata, Rome, Italy
- 4. Department of Biomedicine and Prevention, University of Roma Tor Vergata, Rome, Italy
- 5. IRCCS Fondazione Santa Lucia, andDepartment of Systems Medicine, University of Roma Tor Vergata, Rome, Italy
Description
Background: Synaptopathy is critical in pathophysiology of Parkinson’s disease (PD). Cerebrospinal fluid (CSF) levels of neurogranin (NG) and amyloid-_42 (A_42) are considered markers of synaptic dysfunction in neurodegenerative diseases.
Objective: To evaluate the CSF synaptopathy-related biomarkers, especially the novel A_42/NG ratio, in PD, establishing possible associations with cognitive level and other clinical parameters.
Methods: Levels of NG, A_42, amyloid-_40, total and phosphorylated tau, and A_42/NG ratio were measured in 30 PD patients and 30 controls and correlated with cognitive and motor parameters. The accuracy in distinguishing the cognitive status was determined.
Results:NGandA_42 were significantly reduced in PD, with higherNGlevels in patients with worse cognition. TheA_42/NG ratio showed a direct correlation with Mini-Mental State Examination, independently from age and sex, and differentiated cognitively impaired patients with 92% sensitivity and 71.4% specificity, accuracy higher than NG alone. No correlations resulted with motor disturbances or therapy.
Conclusions: The novel A_42/NG ratio couples either presynaptic or postsynaptic markers of synaptic dysfunction, representing a potential global index of synaptopathy, useful to track cognitive functions in PD.